Neuromuscular Blocking Agents — Competitive Intelligence Brief

Neuromuscular Blocking Agents (Neuromuscular Blocking Agents) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Anesthesiology.

marketed Neuromuscular blocking agent Nicotinic acetylcholine receptor at the neuromuscular junction Anesthesiology Small molecule

Target snapshot

Neuromuscular Blocking Agents (Neuromuscular Blocking Agents) — Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Neuromuscular blocking agents inhibit acetylcholine binding at the neuromuscular junction, preventing muscle contraction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neuromuscular Blocking Agents TARGET	Neuromuscular Blocking Agents	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium dosing	Rocuronium dosing	Clare Hayes-Bradley	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
NMBA - cisatracurium	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction
Deep neuromuscular block	Deep neuromuscular block	University of Medicine and Pharmacy at Ho Chi Minh City	marketed		Nicotinic acetylcholine receptor at the neuromuscular junction
Vecuronium + Atracurium	Vecuronium + Atracurium	Sir Ganga Ram Hospital	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocking agent class)

1. Galderma R&D · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
4. Allergan · 1 drug in this class
5. Seganest · 1 drug in this class
6. University of California, Los Angeles · 1 drug in this class
7. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class